Short Interest in Nyxoah S.A. (NASDAQ:NYXH) Decreases By 17.4%

Nyxoah S.A. (NASDAQ:NYXH) was the recipient of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 58,800 shares, a drop of 17.4% from the October 15th total of 71,200 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average trading volume of 63,200 shares, the short-interest ratio is presently 0.9 days.

Institutional Trading of Nyxoah

Several institutional investors and hedge funds have recently made changes to their positions in the company. Iron Triangle Partners LP bought a new position in Nyxoah during the 1st quarter worth about $3,413,000. CVI Holdings LLC purchased a new stake in shares of Nyxoah in the 2nd quarter worth approximately $1,292,000. Ikarian Capital LLC bought a new position in shares of Nyxoah during the first quarter valued at approximately $684,000. Finally, Kovack Advisors Inc. purchased a new position in Nyxoah during the third quarter valued at approximately $96,000.

Analyst Ratings Changes

NYXH has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Nyxoah in a research report on Tuesday, November 5th. HC Wainwright cut their price target on shares of Nyxoah from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, October 11th. Finally, Oppenheimer reduced their price target on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nyxoah currently has an average rating of “Buy” and a consensus target price of $17.00.

Nyxoah Stock Down 2.5 %

Shares of NASDAQ NYXH opened at $8.22 on Friday. Nyxoah has a twelve month low of $4.00 and a twelve month high of $20.00. The business has a fifty day simple moving average of $9.06 and a two-hundred day simple moving average of $8.72. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.